Journal
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
Volume 23, Issue 3, Pages 547-+Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.hoc.2009.03.009
Keywords
Melanoma; Immunotherapy; Cytokines; Antibodies; Vaccines; Review
Categories
Ask authors/readers for more resources
About 20% of all primary melanomas will spread. The likelihood of metastatic behavior correlates with prognostic factors such as tumor thickness, mitotic index, presence of ulceration, lymphocyte infiltration, age, gender, and anatomic site. Immunotherapies are developed for melanoma patients in stage IV who have distant metastases and in stage II to III patients in the adjuvant micrometastatic setting, where only a fraction of patients have widespread (microscopic) disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available